Visoluten
Research OnlyA cytamin-class peptide supplement derived from ocular (eye) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for vision and eye health support. Contains peptide complexes rather than defined sequences. Some Russian clinical data exists, primarily alongside retinalamin studies.
Eye cytamin · Ocular peptide supplement · A-11 eye peptides
Mostly preclinical · 2 human studies
- Preclinical
- 67%
- Clinical
- 33%
Based on 6 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
"Visoluten" returns zero PubMed results as a named compound; it is an undefined oral cytamin (eye-tissue peptide mixture) with no compound-specific studies, so all evidence below is borrowed from the broader Khavinson ocular peptide class (Retinalamin extract, Epitalon/AEDG). Research Depth 20 (1A=9 documented combination-protocol clinical observation that cannot isolate visoluten's contribution, not a visoluten-specific study; 1B=3 best data uncontrolled/unblinded/confounded high RoB; 1C=2 visoluten-specific human N effectively <50; 1D=3 indirect — always co-administered with retinalamin; 1E=3 modest related preclinical base, PMID 12937684/12802458 on retinal-peptide proliferation/induction, none on visoluten itself). Mechanism 25 (2A=10 target inferred via cytamin gene-regulation theory, no binding data for an undefined mixture; 2B=8 promoter-region DNA-binding pathway characterized for defined peptides PMID 30859383/32019204 not the mixture; 2C=2 no dose-response; 2D=5 in-vitro level for visoluten). Plausibility 51 (3A=14 large leap from undefined oral mixture with unproven bioavailability, ≥1 unproven intermediate link; 3B=14 coherent-neutral with peptide-bioregulator biology; 3C=12 same-class analogy — Retinalamin and Epitalon show retinoprotective effects PMID 12374906/25272779; 3D=11 tightly scoped ocular-support claim). Global Coverage 13 (4A=4 single Russian group for visoluten; 4B=5 one country; 4C=4 <5 visoluten studies; 4D=0 supplement only, no drug-level regulator registration of visoluten itself). Community Experience 21 (5A=3 negligible documented use — dossier reports no meaningful community discussion; 5B=7; 5C=4 no reports to assess; 5D=7 no notable adverse signal over thin exposure). Effectiveness not established: no quantified human efficacy estimate for visoluten and no meaningful community effect signal.
Mechanism of Action
Visoluten is a cytamin-class supplement containing peptide complexes derived from ocular (eye) tissue of young animals. It belongs to the Khavinson bioregulatory peptide framework developed at the St. Petersburg Institute of Bioregulation and Gerontology.
Proposed Mechanisms
- Retinal Support — Claimed to contain tissue-specific peptides that support retinal cell function and metabolism
- Lens Health — Proposed effects on crystalline lens transparency and function
- Ocular Tissue Regulation — Marketed for age-related vision support within the Khavinson bioregulator framework
How Cytamins Work (Theoretical)
Cytamins are oral supplements containing tissue-specific peptide complexes extracted from animal organs. The Khavinson theory proposes that these short peptides (2-4 amino acids) survive digestion, reach target tissues, and regulate gene expression by interacting with DNA promoter regions. This mechanism remains unvalidated by Western research standards.
Relationship to Retinalamin
Visoluten (oral cytamin) and Retinalamin (injectable tissue extract) both target ocular tissue within the Khavinson system. Retinalamin has significantly more clinical evidence, including Russian drug registration for retinal dystrophy and age-related macular degeneration. Visoluten is the oral supplement counterpart, often used as a maintenance product alongside injectable retinalamin courses in Russian clinical practice.
Clinical Context
Russian ophthalmologists from the Khavinson school have published observational studies using combined bioregulator protocols (retinalamin + visoluten + cortexin) for age-related macular degeneration and diabetic retinopathy. However, these studies lack randomization, blinding, and independent replication — making it difficult to attribute effects specifically to visoluten.
Important Limitations
- NOT a defined peptide — contains complex mixture of tissue-derived peptides
- Oral peptide bioavailability is generally very low
- Russian clinical data is observational and does not isolate visoluten’s contribution
- No randomized controlled trials meeting international standards
- NOT a treatment for any eye disease or visual condition
- Not approved by any Western regulatory agency
- Primarily supported by Russian-language literature from a single research group
- Clinical context confounded by combination protocols (always used with retinalamin)
Retinalamin
CompatibleBoth target ocular tissue within the Khavinson framework. Retinalamin is an injectable tissue extract for retinal conditions, while Visoluten is an oral cytamin supplement for general eye support. Often used together in Russian ophthalmologic practice.
Cortexin
CompatibleBoth tissue-derived Khavinson peptide complexes. Cortexin targets neurological tissue while Visoluten targets ocular tissue. Used together in Russian practice for optic nerve conditions.
Epithalon
CompatibleDifferent targets within the Khavinson framework — Epithalon for systemic longevity via telomerase, Visoluten for tissue-specific ocular support.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Visoluten
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.